Direkt zur Hauptnavigation springen Direkt zum Inhalt springen
Letzte Suchanfragen

Ergebnisse für *

Es wurden 3 Ergebnisse gefunden.

Zeige Ergebnisse 1 bis 3 von 3.

Sortieren

  1. The comprehensiveness of the ESHRE/ESGE classification of female genital tract congenital anomalies: A systematic review of cases not classified by the AFS system
    Autor*in: DI SPIEZIO SARDO, ATTILIO ; Campo, R. ; Gordts, S. ; Spinelli, M. ; Cosimato, C. ; Tanos, V. ; Brucker, S. ; Li, T. C. ; Gergolet, M. ; De Angelis, C. ; Gianaroli, L. ; Grimbizis, G.
    Erschienen: 2015

    STUDY QUESTION How comprehensive is the recently published European Society of Human Reproduction and Embryology (ESHRE)/European Society for Gynaecological Endoscopy (ESGE) classification system of female genital anomalies? SUMMARY ANSWER The... mehr

     

    STUDY QUESTION How comprehensive is the recently published European Society of Human Reproduction and Embryology (ESHRE)/European Society for Gynaecological Endoscopy (ESGE) classification system of female genital anomalies? SUMMARY ANSWER The ESHRE/ESGE classification provides a comprehensive description and categorization of almost all of the currently known anomalies that could not be classified properly with the American Fertility Society (AFS) system. WHAT IS KNOWN ALREADY Until now, the more accepted classification system, namely that of the AFS, is associated with serious limitations in effective categorization of female genital anomalies. Many cases published in the literature could not be properly classified using the AFS system, yet a clear and accurate classification is a prerequisite for treatment. STUDY DESIGN, SIZE AND DURATION The CONUTA (CONgenital UTerine Anomalies) ESHRE/ESGE group conducted a systematic review of the literature to examine if those types of anomalies that could not be properly classified with the AFS system could be effectively classified with the use of the new ESHRE/ESGE system. An electronic literature search through Medline, Embase and Cochrane library was carried out from January 1988 to January 2014. Three participants independently screened, selected articles of potential interest and finally extracted data from all the included studies. Any disagreement was discussed and resolved after consultation with a fourth reviewer and the results were assessed independently and approved by all members of the CONUTA group. PARTICIPANTS/MATERIALS, SETTING, METHODS Among the 143 articles assessed in detail, 120 were finally selected reporting 140 cases that could not properly fit into a specific class of the AFS system. Those 140 cases were clustered in 39 different types of anomalies. MAIN RESULTS AND THE ROLE OF CHANCE The congenital anomaly involved a single organ in 12 (30.8%) out of the 39 types of anomalies, while multiple organs and/or segments of Müllerian ducts (complex ...

     
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
  2. Relation of Low Response to Clopidogrel Assessed With Point-of-Care Assay to Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Stenting for Stable Angina Pectoris
    Autor*in: Cuisset, T ; Hamilos, M ; Sarma, J ; Sarno, G ; Wyffels, E ; Vanderheyden, M ; Bartunek, J ; De Bruyne, B ; Wijns, W. ; BARBATO, EMANUELE
    Erschienen: 2008

    Impaired responses to antiplatelet therapy assessed by laboratory tests are associated with an increased risk of recurrent ischemic events after percutaneous coronary intervention (PCI). This study was designed to determine the relation between... mehr

     

    Impaired responses to antiplatelet therapy assessed by laboratory tests are associated with an increased risk of recurrent ischemic events after percutaneous coronary intervention (PCI). This study was designed to determine the relation between responses to aspirin and clopidogrel as assessed by a point-of-care assay (Verify Now, Accumetrics, San Diego, California) and periprocedural myocardial infarction (PMI) in patients undergoing elective PCI for stable angina. One hundred twenty-two consecutive patients undergoing elective coronary stenting prospectively received aspirin 500 mg and clopidogrel 600 mg ≥12 hours before PCI. Clopidogrel response was measured with P2Y12 reaction units (PRUs) and percent inhibition P2Y12 from baseline (percent inhibition P2Y12) and aspirin response with aspirin reaction units (ARUs). Troponin T level was considered positive if it was >0.03 ng/ml. Responses to aspirin and clopidogrel were correlated (r = 0.42, p <0.0001). PMI occurred in 27 patients (22%) who showed significantly lower percent inhibition P2Y12 (25.3 ± 26 vs 38.3 ± 25, p = 0.01) and a trend toward higher PRU values (221 ± 87 vs 193 ± 94, p = 0.21). We did not find any difference for aspirin response as assessed by ARUs in patients with or without PMI (460 ± 82 vs 454 ± 73, p = 0.82). Stratification of percent inhibition P2Y12 isolated a quartile of clopidogrel nonresponders (inhibition P2Y12 <15%) with significantly higher incidence of PMI (44% vs 15%, odds ratio 4.6, 95% confidence interval 1.9 to 11.5, p = 0.001). In conclusion, point-of-care assessment of clopidogrel response reliably predicted PMI after low- to medium-risk elective PCI for stable angina. © 2008 Elsevier Inc. All rights reserved.

     
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
  3. Adipose tissue transcriptome reflects variations between subjects with continued weight loss and subjects regaining weight 6 mo after caloric restriction independent of energy intake.
    Autor*in: Márquez-Quiñones, Adriana ; Mutch, David, ; Debard, Cyrille ; Wang, Ping ; Combes, Marion ; Roussel, Balbine ; Holst, Claus ; Martinez, J Alfredo ; Handjieva-Darlenska, Teodora ; Kalouskova, Pavla ; Jebb, Susan ; Babalis, Dimitris ; Pfeiffer, Andreas, ; Larsen, Thomas, ; Astrup, Arne ; Saris, Wim, ; Mariman, Edwin ; Clément, Karine ; Vidal, Hubert ; Langin, Dominique ; Viguerie, Nathalie
    Erschienen: 2010
    Verlag:  HAL CCSD ; Oxford University Press

    International audience ; BACKGROUND: The mechanisms underlying body weight evolution after diet-induced weight loss are poorly understood. OBJECTIVE: We aimed to identify and characterize differences in the subcutaneous adipose tissue (SAT)... mehr

     

    International audience ; BACKGROUND: The mechanisms underlying body weight evolution after diet-induced weight loss are poorly understood. OBJECTIVE: We aimed to identify and characterize differences in the subcutaneous adipose tissue (SAT) transcriptome of subjects with different weight changes after energy restriction-induced weight loss during 6 mo on 4 different diets. DESIGN: After an 8-wk low-calorie diet (800 kcal/d), we randomly assigned weight-reduced obese subjects from 8 European countries to receive 4 diets that differed in protein and glycemic index content. In addition to anthropometric and plasma markers, SAT biopsies were taken at the beginning [clinical investigation day (CID) 2] and end (CID3) of the weight follow-up period. Microarray analysis was used to define SAT gene expression profiles at CID2 and CID3 in 22 women with continued weight loss (successful group) and in 22 women with weight regain (unsuccessful group) across the 4 dietary arms. RESULTS: Differences in SAT gene expression patterns between successful and unsuccessful groups were mainly due to weight variations rather than to differences in dietary macronutrient content. An analysis of covariance with total energy intake as a covariate identified 1338 differentially expressed genes. Cellular growth and proliferation, cell death, cellular function, and maintenance were the main biological processes represented in SAT from subjects who regained weight. Mitochondrial oxidative phosphorylation was the major pattern associated with continued weight loss. CONCLUSIONS: The ability to control body weight loss independent of energy intake or diet composition is reflected in the SAT transcriptome. Although cell proliferation may be detrimental, a greater mitochondrial energy gene expression is suggested as being beneficial for weight control. This trial was registered at clinicaltrials.gov as NCT00390637.

     
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format